Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 1c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Kepler Cheuvreux Starts Jet2 plc (JET2:LN) (DRTGF) at Buy
• JPMorgan Downgrades Rockwool (ROCKB:DC) (RKWBF) to Neutral